Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.
about
Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic ImplicationsPLK1, A Potential Target for Cancer TherapyDasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instabilityRNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma.Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.Polo-like kinase 1, a new therapeutic target in hepatocellular carcinomaPolo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma.Gene signatures in hepatocellular carcinoma (HCC).Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cellsInduction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up.PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9Polo-like kinase 1 as target for cancer therapy.Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.
P2860
Q28076060-5298AACA-6508-4CCE-A091-2EED5F95D55AQ28078772-5693448B-F44F-4199-A15F-A7E3583ED372Q33577628-0D484D93-C1CB-42DC-96F2-815FBF5FA511Q33659911-EFDB02D6-886E-4D78-80AE-9AED0E7E6583Q33662727-3168E320-FA51-4C3E-8526-2F686DE413ABQ33820846-0F1CA1B9-20EE-433D-B54A-5B0945E510C1Q35828495-8B70265C-ACCD-4ECE-9070-05708F614FBAQ36062154-FABE2B45-44BF-401C-9844-BA9BC3B7AED4Q36105529-647671E2-ED9C-417A-9E42-CEF3907D3EADQ36577379-F3F636BD-900A-42B6-8D73-EAD41F4BA88AQ36962809-216AC28F-C9BD-4613-8A2A-5AFAF1A6B895Q37447866-AB0BD31B-6210-4969-BF54-FAA953898DC9Q37693314-D4475E8A-F198-4542-AECA-9F05A77C3B1DQ37790070-A2B6FDBA-AD3C-4CC0-B368-B2C5F0724292Q38637013-97FD8A11-B489-42D9-BBF4-0E01445FF4FEQ38671515-FAC690F5-4733-47CA-9643-9D00416C98EFQ39141522-A6600DD0-B01E-4EC1-B700-5413250AB43CQ39547514-2072647E-D97D-427C-BB0D-9E759D66D509Q39599711-1B5EF9F1-748F-4EBA-8AAC-3C43FD841710Q39633115-F0EB2537-BA23-4C26-8C2E-2ADC1E85DDFDQ41170688-AF5CD965-BAED-40D1-8E09-2FF6A4766D84Q41299020-331CF481-01DF-47F8-A26F-84ABB7A07286Q41813783-70ACB7F0-C65D-4F47-B810-8A3B9CF6F647Q48031390-381C0673-3215-47A1-A677-B6336ADD109FQ49402953-4892BCD0-64ED-43C5-8E50-1C0B255690E7Q53066951-DF6B95C3-BDCC-4B47-BD10-E91D662E5E01
P2860
Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@en
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@nl
type
label
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@en
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@nl
prefLabel
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@en
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@nl
P2093
P2860
P356
P1476
Overexpression of polo-like ki ...... tocellular carcinoma patients.
@en
P2093
De-Wu Zhong
Xiong-Ying Miao
P2860
P304
P356
10.3748/WJG.15.4177
P407
P577
2009-09-01T00:00:00Z